⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CABA News
Cabaletta Bio, Inc. Common Stock
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
globenewswire.com
CABA
Form 8-K
sec.gov
CABA
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
globenewswire.com
CABA
Form 8-K
sec.gov
CABA
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
globenewswire.com
CABA
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
globenewswire.com
CABA
Form 8-K
sec.gov
CABA
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
businesswire.com
CABA
Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
BIIB
NVS
VTRS
UCB
BMY
ABBV
AZN
CABA
AUR
GSK
VERA
KYMR
NKTR
VRTX
ARWR